Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure Post author: Post published:September 3, 2024 Post category:uncategorized MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients. You Might Also Like Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer July 11, 2024 New insights into the role of gamma-delta T cells across 33 cancer types revealed October 4, 2024 Metrion Biosciences closes £3.7m new equity financing December 20, 2023
Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer July 11, 2024